Dear Editor:

We read with great interest the article by Mathew et al evaluating the potential metabolic drug-drug interactions with fucoidan from *Undaria pinnatifida* and *Fucus vesiculosus*.^[@bibr1-1534735419876325]^ Phase I as well as phase II enzymes activities have been assessed for inhibition and induction effects of *Undaria pinnatifida* and *Fucus vesiculosus* extracts.

Induction experiments of cytochromes P450 (CYP) were performed on cryopreserved human hepatocytes using a cocktail of specific probe drugs in the presence of rifampicin, a potent inducer of multiple enzymes. As stated in the phase I enzymes induction assays methods section, the cocktail of probe drugs was composed of "dextromethorphan for CYP2C8/2C9, diclofenac for CYP2D6, and docetaxel for CYP3A4."

First of all, it is widely accepted that CYP2D6 is not inducible.^[@bibr2-1534735419876325]^ Induction experiments for CYP2D6 are therefore not required for new chemical entities by the regulatory agencies. Recently, an article published by Farooq et al^[@bibr3-1534735419876325]^ indicating a potential induction of CYP2D6 by corticosteroids has been withdrawn because of a retraction of the authors as they were unable to reproduce the results.^[@bibr4-1534735419876325]^

Second, there is confusion in the association between the probe drugs that were used and their related metabolic pathways. In fact, dextromethorphan is a specific probe drug for CYP2D6 (FDA \[Food Drug Administration\] guidance), diclofenac for CYP2C9 (FDA guidance), and docetaxel for CYP 3A4/5.^[@bibr5-1534735419876325]^ Dextromethorphan is mainly metabolized to dextrorphan by CYP2D6, and to a lesser extent to 3-methoxymorphinan by CYP3A4/5.^[@bibr6-1534735419876325]^ Diclofenac is metabolized to 4′-hydroxy-diclofenac by CYP2C9^[@bibr7-1534735419876325]^ and docetaxel is metabolized to hydroxydocetaxel by CYP3A4/5.^[@bibr8-1534735419876325]^

Third, there is no specific probe drug for CYP2C8 in the used cocktail. The validated probe drugs for this enzyme are paclitaxel, amodiaquine (FDA guidance), repaglinide, montelukast, and pioglitazone.^[@bibr9-1534735419876325]^ Therefore, any reference to CYP2C8 in the article should be interpreted with caution.

Finally, in the CYP inhibition assays, only 2 substrates (dibenzylfluorescein and 3-(2-(N,N-diethyl-Nmethylammonium)ethyl)-7-methoxy-4-methylcoumarin iodide) were used as substrates for CYP2C8, CYP2C9, CYP3A4/5, and CYP2D6 without giving any explanation about the metabolic pathways and the specificity regarding the 4 enzymes. As dibenzylfluorescein is a substrate of CYP 2C9, 2C8, and to a lower extent of CYP 3A4^[@bibr10-1534735419876325]^ and 3-(2-(N,N-diethyl-N-methylammonium)ethyl)-7-methoxy-4-methylcoumarin iodide is specific to CYP 2D6.^[@bibr10-1534735419876325],[@bibr11-1534735419876325]^ Moreover, Reference 11 in the article^[@bibr12-1534735419876325]^ is not related to this assay at all.

Therefore, conclusions from the present article should be interpreted with great caution and should not be translated into any clinical interpretation.
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